Module contents

Module home
Module introduction
Pre-module test
Module information
About the author

 

Section 1: Treatment of antidepressant-induced sexual dysfunction

(1.1) Section 1: Treatment of antidepressant-induced sexual dysfunction

(1.2) Before you begin

(1.3) A woman who thought she was 'frigid'

(1.4) A woman who thought she was 'frigid' (cont..)

(1.5) A woman who thought she was 'frigid' (cont..)

(1.6) A woman who thought she was 'frigid' (cont..)

(1.7) Reflection

(1.8) Reflection (cont..)

(1.9) Overview of treatment strategies

(1.10) Modification of the current antidepressive treatment

(1.11) Treatment of sexual dysfunction targeting specific receptors

(1.12) Other treatments

(1.13) Reflection

(1.14) Reflection

(1.15) Pharmacological reversal - target noradrenaline

(1.16) Target: noradrenaline

(1.17) Outlook - interactive diagram

(1.18) Reflection

(1.19) Pharmacological reversal - target serotonin

(1.20) Target: serotonin

(1.21) Reflection

(1.22) Pharmacological reversal - target dopamine

(1.23) Target: dopamine

(1.24) Reflection

(1.25) Pharmacological reversal - other targets

(1.26) Other targets

(1.27) Reflection

(1.28) Pharmacological reversal - target nitric oxide (NO)

(1.29) Phosphodiesterase5 (PD5)-inhibitors

(1.30) It all starts with nitric oxide…

(1.31) PD5-inhibitors contraindications

(1.32) Yet another story...

(1.33) Section 1: Recap

(1.34) Section 1: Summary

 

Section 2: Other treatments for sexual dysfunction

(2.1) Section 2: Other treatments for sexual dysfunction

(2.2) Reflection

(2.3) Reflection (cont..)

(2.4) Hormone treatments for women

(2.5) Reflection

(2.6) Reflection (cont..)

(2.7) Hormone treatments for women - potential side effects

(2.8) Reflection

(2.9) Reflection (cont..)

(2.10) Hormone treatments for men

(2.11) Outlook

(2.12) Reflection

(2.13) Reflection (cont..)

(2.14) Complementary medicines for sexual dysfunction

(2.15) Reflection

(2.16) Reflection (cont..)

(2.17) Reflection

(2.18) Reflection (cont..)

(2.19) LavigraTM

(2.20) ArginMax

(2.21) ProvestraTM

(2.22) Outlook

(2.23) Section 2: Recap

(2.24) Section 2: Summary

 

Section 3: Formal aspects of prescribing for sexual dysfunction

(3.1) Section 3: Formal aspects of prescribing for sexual dysfunction

(3.2) Reflection

(3.3) Reflection (cont..)

(3.4) The GMC requirements for prescribing unlicensed medications

(3.5) The GMC requirements for prescribing a medicine for use
outside the terms of its license

(3.6) Informed consent

(3.7) Quick recap

(3.8) Quick recap (cont..)

(3.9) Reflection

(3.10) Reflection (cont..)

(3.11) The BNF requirements for prescribing for erectile dysfunction

(3.12) The severe distress clause

(3.13) Section 3: Recap

(3.14) Section 3: Summary

 

Module summary

Conclusions

Module test

Take-home notes

References

Acknowledgements

Send feedback

 

© 2008 Royal College of Psychiatrists